Skip to main content

Corbus Pharmaceuticals Holdings, Inc.

corporate_fare Company Profile

Corbus Pharmaceuticals Holdings, Inc.

CRBP·NASDAQ·Life Sciences·CIK 0001595097

Corbus Pharmaceuticals Holdings, Inc. is a clinical stage company developing new therapies for oncology and obesity. The company focuses on innovative scientific approaches to well-understood biological pathways to help people with serious illnesses. Corbus' pipeline includes two main candidates: CRB-701 and CRB-913. CRB-701 is a next-generation antibody drug conjugate (ADC) designed to target Nectin-4 expression on cancer cells, releasing a cytotoxic payload of monomethyl auristatin E (MMAE). In February 2023, Corbus licensed CRB-701 from CSPC Megalith Biopharmaceutical Co. Ltd. for development and commercialization in the U.S., Canada, the European Union (including the European Free Trade Area), the U.K., and Australia. Corbus is conducting a Phase 1/2 study in the U.S. and Europe for patients with advanced solid tumors associated with Nectin-4 expression, with the dose expansion phase currently ongoing. In June 2025, the company began dosing participants in a PD-1 combination arm, administering CRB-701 with Keytruda® (pembrolizumab). The U.S. Food and Drug Administration (FDA) granted fast track designation for CRB-701 for relapsed or refractory metastatic cervical cancer in December 2024, and for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) previously treated with platinum-based chemotherapy and an anti-PD(L)-1 therapy in September 2025. CSPC is also investigating CRB-701 in a Phase 3 clinical trial for cervical cancer patients in China. CRB-913 is a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist intended for the treatment of obesity.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 31 items for CRBP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for CRBP spans 8-K, 424B5, 10-Q.

Recent high-impact activity:

  • Corbus Details Full CANYON-1 Data: 5% Weight Loss at 60 mg, Clean Psychiatric Safety
  • Corbus Posts $37.8M Q3 Loss; $115.3M Cash Funds Operations Into 2028
  • Corbus Doses First Patient in Registrational TEMPO-1 Trial for CRB-701
  • Corbus CRB-913 Hits 5% Weight Loss in Phase 1b Obesity Trial With Clean Safety
  • Corbus' CRB-913 Obesity Drug Hits 5% Weight Loss in Phase 1b, Beats Safety Bar

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$78.54M
Diluted EPS
-$5.90
Op. Cash Flow
-$64.49M
Free Cash Flow
-$64.5M
Operating Income
-$85.31M
Cash & Equivalents
$28.49M
Debt / Equity
0.00×
Shares Outstanding
17.61M sh
Source: 10-K · filed 2026-03-09 · accession 0001193125-26-098530

Short Interest & Short Volume

3.48 days to cover

FINRA reported short interest of 3,244,229 shares in CRBP as of the October 30, 2026 settlement, a 19.5% increase from the prior period — about 3.5 days to cover at its recent average daily volume. On November 20, 2026, 49.5% of CRBP volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)3,244,229 shares as of October 30, 2026
Change vs prior period▲ 19.5%
Days to cover3.48 at avg daily volume of 933,143
Daily short volume (FINRA facilities)49.5% of 380,844 shares on November 20, 2026
5-day average short volume45.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for CRBP, detected from its recent SEC filings · based on capital-structure filings through 2026-08-07.

1 recent capital raiseATM program

$127.5M ATM Program Activated · Potential 70% Share Count Increase

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with C →
$2.09 +1.46% today
52-week range · as of 2026-11-16 $2.09 – $12.88
Market cap
$42.45M
Volume
1.4M (1.3× avg)
3-mo avg 1.1M
Live data · 2026-11-22 04:53 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CRBP - Latest Insights

CRBP
Nov 16, 2026, 8:08 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.45
Real-time Price: $2.09 info
Change: -$1.36 (-39%) info
Market Cap: $42.45M info
CRBP
Nov 10, 2026, 8:08 AM EST
Filing Type: 8-K
Importance Score:
7
Updated Nov 10, 9:31 AM ET — Corbus's Q3 loss of $1.81 per share missed the $1.21 mean analyst estimate; revenue was zero versus $1.25M expected.
Price at Filing: $3.52
Real-time Price: $2.09 info
Change: -$1.43 (-41%) info
Market Cap: $42.45M info
CRBP
Sep 29, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.08
Real-time Price: $2.09 info
Change: -$4.99 (-70%) info
Market Cap: $42.45M info
CRBP
Sep 14, 2026, 7:06 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.26
Real-time Price: $2.09 info
Change: -$7.17 (-77%) info
Market Cap: $42.45M info
CRBP
Sep 14, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $8.91
Real-time Price: $2.09 info
Change: -$6.82 (-77%) info
Market Cap: $42.45M info
CRBP
Aug 07, 2026, 4:33 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $9.77
Real-time Price: $2.09 info
Change: -$7.68 (-79%) info
Market Cap: $42.45M info
CRBP
Aug 06, 2026, 4:35 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.65
Real-time Price: $2.09 info
Change: -$7.56 (-78%) info
Market Cap: $42.45M info
CRBP
Aug 06, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.07
Real-time Price: $2.09 info
Change: -$6.98 (-77%) info
Market Cap: $42.45M info
CRBP
Aug 06, 2026, 8:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $9.07
Real-time Price: $2.09 info
Change: -$6.98 (-77%) info
Market Cap: $42.45M info
CRBP
Jul 28, 2026, 8:07 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $9.21
Real-time Price: $2.09 info
Change: -$7.12 (-77%) info
Market Cap: $42.45M info
CRBP
Jul 06, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.00
Real-time Price: $2.09 info
Change: -$6.91 (-77%) info
Market Cap: $42.45M info
CRBP
May 26, 2026, 2:59 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $7.81
Real-time Price: $2.09 info
Change: -$5.72 (-73%) info
Market Cap: $42.45M info
CRBP
May 26, 2026, 8:56 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $10.31
Real-time Price: $2.09 info
Change: -$8.22 (-80%) info
Market Cap: $42.45M info
CRBP
May 26, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $11.50
Real-time Price: $2.09 info
Change: -$9.41 (-82%) info
Market Cap: $42.45M info
CRBP
May 21, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $10.00
Real-time Price: $2.09 info
Change: -$7.91 (-79%) info
Market Cap: $42.45M info
CRBP
May 14, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $11.46
Real-time Price: $2.09 info
Change: -$9.37 (-82%) info
Market Cap: $42.45M info
CRBP
May 12, 2026, 4:50 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $11.42
Real-time Price: $2.09 info
Change: -$9.33 (-82%) info
Market Cap: $42.45M info
CRBP
May 12, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $11.65
Real-time Price: $2.09 info
Change: -$9.56 (-82%) info
Market Cap: $42.45M info
CRBP
May 12, 2026, 8:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $11.70
Real-time Price: $2.09 info
Change: -$9.61 (-82%) info
Market Cap: $42.45M info
CRBP
Apr 16, 2026, 4:19 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.14
Real-time Price: $2.09 info
Change: -$8.05 (-79%) info
Market Cap: $42.45M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets